[1]
Kolb SJ, Kissel JT. Spinal muscular atrophy: a timely review. Archives of neurology. 2011 Aug:68(8):979-84. doi: 10.1001/archneurol.2011.74. Epub 2011 Apr 11
[PubMed PMID: 21482919]
[2]
Adam MP, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, Prior TW, Leach ME, Finanger E. Spinal Muscular Atrophy. GeneReviews(®). 1993:():
[PubMed PMID: 20301526]
[3]
D'Amico A, Mercuri E, Tiziano FD, Bertini E. Spinal muscular atrophy. Orphanet journal of rare diseases. 2011 Nov 2:6():71. doi: 10.1186/1750-1172-6-71. Epub 2011 Nov 2
[PubMed PMID: 22047105]
[4]
Darras BT. Spinal muscular atrophies. Pediatric clinics of North America. 2015 Jun:62(3):743-66. doi: 10.1016/j.pcl.2015.03.010. Epub 2015 Apr 11
[PubMed PMID: 26022173]
[5]
Dubowitz V. Ramblings in the history of spinal muscular atrophy. Neuromuscular disorders : NMD. 2009 Jan:19(1):69-73. doi: 10.1016/j.nmd.2008.10.004. Epub 2008 Oct 31
[PubMed PMID: 18951794]
[6]
Lefebvre S, Bürglen L, Reboullet S, Clermont O, Burlet P, Viollet L, Benichou B, Cruaud C, Millasseau P, Zeviani M. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995 Jan 13:80(1):155-65
[PubMed PMID: 7813012]
[7]
Mailman MD, Heinz JW, Papp AC, Snyder PJ, Sedra MS, Wirth B, Burghes AH, Prior TW. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genetics in medicine : official journal of the American College of Medical Genetics. 2002 Jan-Feb:4(1):20-6. doi: 10.1097/00125817-200201000-00004. Epub
[PubMed PMID: 11839954]
[8]
Prior TW, Krainer AR, Hua Y, Swoboda KJ, Snyder PC, Bridgeman SJ, Burghes AH, Kissel JT. A positive modifier of spinal muscular atrophy in the SMN2 gene. American journal of human genetics. 2009 Sep:85(3):408-13. doi: 10.1016/j.ajhg.2009.08.002. Epub 2009 Aug 27
[PubMed PMID: 19716110]
[9]
Ludolph AC, Wurster CD. Therapeutic advances in SMA. Current opinion in neurology. 2019 Oct:32(5):777-781. doi: 10.1097/WCO.0000000000000738. Epub
[PubMed PMID: 31425176]
Level 3 (low-level) evidence
[10]
Crawford TO, Pardo CA. The neurobiology of childhood spinal muscular atrophy. Neurobiology of disease. 1996 Apr:3(2):97-110
[PubMed PMID: 9173917]
[11]
Zaldívar T, Montejo Y, Acevedo AM, Guerra R, Vargas J, Garofalo N, Alvarez R, Alvarez MA, Hardiman O. Evidence of reduced frequency of spinal muscular atrophy type I in the Cuban population. Neurology. 2005 Aug 23:65(4):636-8
[PubMed PMID: 16116135]
[12]
Prior TW. Spinal muscular atrophy: newborn and carrier screening. Obstetrics and gynecology clinics of North America. 2010 Mar:37(1):23-36, Table of Contents. doi: 10.1016/j.ogc.2010.03.001. Epub
[PubMed PMID: 20494255]
[13]
Kolb SJ, Battle DJ, Dreyfuss G. Molecular functions of the SMN complex. Journal of child neurology. 2007 Aug:22(8):990-4
[PubMed PMID: 17761654]
[14]
Bowerman M, Becker CG, Yáñez-Muñoz RJ, Ning K, Wood MJA, Gillingwater TH, Talbot K, UK SMA Research Consortium. Therapeutic strategies for spinal muscular atrophy: SMN and beyond. Disease models & mechanisms. 2017 Aug 1:10(8):943-954. doi: 10.1242/dmm.030148. Epub
[PubMed PMID: 28768735]
[15]
Kolb SJ, Kissel JT. Spinal Muscular Atrophy. Neurologic clinics. 2015 Nov:33(4):831-46. doi: 10.1016/j.ncl.2015.07.004. Epub
[PubMed PMID: 26515624]
[16]
Wijngaarde CA, Blank AC, Stam M, Wadman RI, van den Berg LH, van der Pol WL. Cardiac pathology in spinal muscular atrophy: a systematic review. Orphanet journal of rare diseases. 2017 Apr 11:12(1):67. doi: 10.1186/s13023-017-0613-5. Epub 2017 Apr 11
[PubMed PMID: 28399889]
Level 1 (high-level) evidence
[17]
Rudnik-Schöneborn S, Goebel HH, Schlote W, Molaian S, Omran H, Ketelsen U, Korinthenberg R, Wenzel D, Lauffer H, Kreiss-Nachtsheim M, Wirth B, Zerres K. Classical infantile spinal muscular atrophy with SMN deficiency causes sensory neuronopathy. Neurology. 2003 Mar 25:60(6):983-7
[PubMed PMID: 12654964]
[18]
Zerres K, Rudnik-Schöneborn S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Archives of neurology. 1995 May:52(5):518-23
[PubMed PMID: 7733848]
[19]
von Gontard A, Zerres K, Backes M, Laufersweiler-Plass C, Wendland C, Melchers P, Lehmkuhl G, Rudnik-Schöneborn S. Intelligence and cognitive function in children and adolescents with spinal muscular atrophy. Neuromuscular disorders : NMD. 2002 Feb:12(2):130-6
[PubMed PMID: 11738354]
[20]
Dubowitz V. Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. 1999:3(2):49-51
[PubMed PMID: 10700538]
[21]
Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: diagnosis and management in a new therapeutic era. Muscle & nerve. 2015 Feb:51(2):157-67. doi: 10.1002/mus.24497. Epub 2014 Dec 16
[PubMed PMID: 25346245]
[22]
Zerres K, Rudnik-Schöneborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. Journal of the neurological sciences. 1997 Feb 27:146(1):67-72
[PubMed PMID: 9077498]
[23]
Piepers S,van den Berg LH,Brugman F,Scheffer H,Ruiterkamp-Versteeg M,van Engelen BG,Faber CG,de Visser M,van der Pol WL,Wokke JH, A natural history study of late onset spinal muscular atrophy types 3b and 4. Journal of neurology. 2008 Sep;
[PubMed PMID: 18575920]
[24]
Taylor JL, Lee FK, Yazdanpanah GK, Staropoli JF, Liu M, Carulli JP, Sun C, Dobrowolski SF, Hannon WH, Vogt RF. Newborn blood spot screening test using multiplexed real-time PCR to simultaneously screen for spinal muscular atrophy and severe combined immunodeficiency. Clinical chemistry. 2015 Feb:61(2):412-9. doi: 10.1373/clinchem.2014.231019. Epub 2014 Dec 11
[PubMed PMID: 25502182]
[25]
Han JJ, McDonald CM. Diagnosis and clinical management of spinal muscular atrophy. Physical medicine and rehabilitation clinics of North America. 2008 Aug:19(3):661-80, xii. doi: 10.1016/j.pmr.2008.02.004. Epub
[PubMed PMID: 18625423]
[26]
Schroth MK. Special considerations in the respiratory management of spinal muscular atrophy. Pediatrics. 2009 May:123 Suppl 4():S245-9. doi: 10.1542/peds.2008-2952K. Epub
[PubMed PMID: 19420154]
[27]
Wang CH, Finkel RS, Bertini ES, Schroth M, Simonds A, Wong B, Aloysius A, Morrison L, Main M, Crawford TO, Trela A, Participants of the International Conference on SMA Standard of Care. Consensus statement for standard of care in spinal muscular atrophy. Journal of child neurology. 2007 Aug:22(8):1027-49
[PubMed PMID: 17761659]
Level 3 (low-level) evidence
[28]
Durkin ET, Schroth MK, Helin M, Shaaban AF. Early laparoscopic fundoplication and gastrostomy in infants with spinal muscular atrophy type I. Journal of pediatric surgery. 2008 Nov:43(11):2031-7. doi: 10.1016/j.jpedsurg.2008.05.035. Epub
[PubMed PMID: 18970936]
[29]
Sproule DM, Montes J, Montgomery M, Battista V, Koenigsberger D, Shen W, Punyanitya M, De Vivo DC, Kaufmann P. Increased fat mass and high incidence of overweight despite low body mass index in patients with spinal muscular atrophy. Neuromuscular disorders : NMD. 2009 Jun:19(6):391-6. doi: 10.1016/j.nmd.2009.03.009. Epub 2009 May 7
[PubMed PMID: 19427208]
[30]
Davis RH, Godshall BJ, Seffrood E, Marcus M, LaSalle BA, Wong B, Schroth MK, Swoboda KJ. Nutritional practices at a glance: spinal muscular atrophy type I nutrition survey findings. Journal of child neurology. 2014 Nov:29(11):1467-72. doi: 10.1177/0883073813503988. Epub 2013 Oct 4
[PubMed PMID: 24097849]
Level 3 (low-level) evidence
[31]
Haaker G, Fujak A. Proximal spinal muscular atrophy: current orthopedic perspective. The application of clinical genetics. 2013 Nov 14:6(11):113-20. doi: 10.2147/TACG.S53615. Epub 2013 Nov 14
[PubMed PMID: 24399883]
Level 3 (low-level) evidence
[32]
Claborn MK, Stevens DL, Walker CK, Gildon BL. Nusinersen: A Treatment for Spinal Muscular Atrophy. The Annals of pharmacotherapy. 2019 Jan:53(1):61-69. doi: 10.1177/1060028018789956. Epub 2018 Jul 16
[PubMed PMID: 30008228]
[33]
Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC, ENDEAR Study Group. Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy. The New England journal of medicine. 2017 Nov 2:377(18):1723-1732. doi: 10.1056/NEJMoa1702752. Epub
[PubMed PMID: 29091570]
[34]
Malone DC, Dean R, Arjunji R, Jensen I, Cyr P, Miller B, Maru B, Sproule DM, Feltner DE, Dabbous O. Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. Journal of market access & health policy. 2019:7(1):1601484. doi: 10.1080/20016689.2019.1601484. Epub 2019 May 8
[PubMed PMID: 31105909]
[35]
Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, Kissel JT, Nagendran S, L'Italien J, Sproule DM, Wells C, Cardenas JA, Heitzer MD, Kaspar A, Corcoran S, Braun L, Likhite S, Miranda C, Meyer K, Foust KD, Burghes AHM, Kaspar BK. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. The New England journal of medicine. 2017 Nov 2:377(18):1713-1722. doi: 10.1056/NEJMoa1706198. Epub
[PubMed PMID: 29091557]
[36]
Mahajan R. Onasemnogene Abeparvovec for Spinal Muscular Atrophy: The Costlier Drug Ever. International journal of applied & basic medical research. 2019 Jul-Sep:9(3):127-128. doi: 10.4103/ijabmr.IJABMR_190_19. Epub
[PubMed PMID: 31392173]
[37]
Hoy SM. Onasemnogene Abeparvovec: First Global Approval. Drugs. 2019 Jul:79(11):1255-1262. doi: 10.1007/s40265-019-01162-5. Epub
[PubMed PMID: 31270752]
[38]
Ratni H, Ebeling M, Baird J, Bendels S, Bylund J, Chen KS, Denk N, Feng Z, Green L, Guerard M, Jablonski P, Jacobsen B, Khwaja O, Kletzl H, Ko CP, Kustermann S, Marquet A, Metzger F, Mueller B, Naryshkin NA, Paushkin SV, Pinard E, Poirier A, Reutlinger M, Weetall M, Zeller A, Zhao X, Mueller L. Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ( SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA). Journal of medicinal chemistry. 2018 Aug 9:61(15):6501-6517. doi: 10.1021/acs.jmedchem.8b00741. Epub 2018 Jul 25
[PubMed PMID: 30044619]
[39]
Chen TH. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand? International journal of molecular sciences. 2020 May 7:21(9):. doi: 10.3390/ijms21093297. Epub 2020 May 7
[PubMed PMID: 32392694]
[40]
Bowerman M, Swoboda KJ, Michalski JP, Wang GS, Reeks C, Beauvais A, Murphy K, Woulfe J, Screaton RA, Scott FW, Kothary R. Glucose metabolism and pancreatic defects in spinal muscular atrophy. Annals of neurology. 2012 Aug:72(2):256-68. doi: 10.1002/ana.23582. Epub
[PubMed PMID: 22926856]